Drug intelligence / Profile preview

CLU-RX-OLE

Development stage
Phase 3
Lead developer
Roxall Medizin
Administration
Subcutaneous
01

Overview

CLU-RX-OLE is a cluster-immunotherapy allergoid developed by ROXALL Medizin GmbH for the treatment of allergic rhinitis and allergic rhinoconjunctivitis triggered by *Olea europaea* (olive tree) pollen. It consists of chemically modified pollen extracts (allergoids) adsorbed onto aluminum hydroxide. The chemical modification, typically achieved using glutaraldehyde, reduces the allergen's IgE-binding capacity, thereby lowering the risk of systemic allergic reactions while preserving the T-cell epitopes necessary for inducing immunological tolerance. The "cluster" designation refers to an accelerated updosing schedule where multiple injections are administered at short intervals, allowing patients to reach the maintenance dose more quickly than traditional subcutaneous immunotherapy (SCIT) protocols. The product aims to shift the immune response from a Th2-mediated allergic profile to a Th1/Treg-mediated tolerant profile.

Brand names
CLUSTOID
Other names
Olea europaea allergoidOlive pollen allergoid

Beyond the preview

Go deeper on CLU-RX-OLE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CLU-RX-OLE.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call